Noah L. Rosenberg net worth and biography

Noah Rosenberg Biography and Net Worth

Dr. Rosenberg brings to Verrica more than 30 years of clinical and therapeutic development experience. He has led multiple global drug approvals across a number of therapeutic areas, including dermatology.

Dr. Rosenberg has served as chief medical officer for several public and private biotech companies, and has been responsible for the clinical development and medical strategy for pipeline candidates and multiple product launches. He most recently served as CMO at Travere Therapeutics, leading the team responsible for the successful approval of Filspari, and previously led development of Xepi, a topical antibiotic for the treatment of impetigo, at Medimetriks. Earlier in his career, Dr. Rosenberg held leadership positions with Esperion Therapeutics, Forest Research Institute, Sanofi Aventis and Pfizer, where he focused on cardiovascular/metabolism drug development.

Dr. Rosenberg completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai. Dr. Rosenberg holds an M.D. from Drexel University College of Medicine and received his B.A. from Johns Hopkins University.

What is Noah L. Rosenberg's net worth?: The estimated net worth of Noah L. Rosenberg is at least $30.49 thousand as of August 17th, 2026. Dr. Rosenberg owns 6,557 shares of Verrica Pharmaceuticals stock worth more than $30,490 as of September 18th. This net worth evaluation does not reflect any other assets that Dr. Rosenberg may own. Learn More about Noah L. Rosenberg's net worth.
How do I contact Noah L. Rosenberg?: The corporate mailing address for Dr. Rosenberg and other Verrica Pharmaceuticals executives is 44 West Gay Street, Suite 400, West Chester, PA. Verrica Pharmaceuticals can also be reached via phone at (484) 453-3300 and via email at [email protected]. Learn More on Noah L. Rosenberg's contact information.
Has Noah L. Rosenberg been buying or selling shares of Verrica Pharmaceuticals?: In the last ninety days, Noah L. Rosenberg has bought $30,609.60 in Verrica Pharmaceuticals stock. Most recently, on Tuesday, August 18th, Noah L. Rosenberg bought 2,030 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $4.92 per share, with a total value of $9,987.60. Following the completion of the transaction, the chief marketing officer now directly owns 8,587 shares of the company's stock, valued at $42,248.04. Learn More on Noah L. Rosenberg's trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), Jayson Rieger (CEO), Noah Rosenberg (CMO), Ted White (CEO), and David Zawitz (COO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 9 times. They purchased a total of 4,247,576 shares worth more than $18,017,266.64. The most recent insider tranaction occured on August, 18th when CMO Noah L. Rosenberg bought 2,030 shares worth more than $9,987.60. Insiders at Verrica Pharmaceuticals own 52.9% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 8/18/2026.

Noah L. Rosenberg Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/18/2026	Buy	2,030	$4.92	$9,987.60	8,587
8/17/2026	Buy	4,200	$4.91	$20,622.00	6,557
11/25/2025	Buy	2,357	$4.24	$9,993.68	2,357

Noah L. Rosenberg Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $4.65

$4.57

$4.79

50 Day Range

MA: $5.22

$4.53

$6.26

2 Week Range

Now: $4.65

$3.28

$9.82

Volume

41,343 shs

Average Volume

94,937 shs

Market Capitalization

$79.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49